Assessing the risk of cervical neoplasia in the post-HPV vaccination era.

导出 OA

翻译打印收藏纠错

第一作者： Matti,Lehtinen

第一单位： Medical Faculty, Tampere University, Tampere, Finland.

作者： Matti,Lehtinen ^[1] ; Ville N,Pimenoff ^[2] ; Belinda,Nedjai ^[2] ; Karolina,Louvanto ^[3] ; Lisanne,Verhoef ^[1] ; Daniëlle A M,Heideman ^[4] ; Mariam,El-Zein ^[5] ; Martin,Widschwendter ^[6] ; Joakim,Dillner ^[5]

作者单位： Medical Faculty, Tampere University, Tampere, Finland. ^[1] Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. ^[2] Wolfson Institute of Population Health, Queen Mary University of London, London, UK. ^[3] Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland. ^[4] Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ^[5] Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. ^[6] Division of Cancer Epidemiology, McGill University, Montreal, Canada. ^[7] European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Hall in Tirol, Austria. ^[8] Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria. ^[9] Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK. ^[10] Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden. ^[11]

关键词 cervical cancer epigenetics gynecological cancers human papillomavirus methylation